☆ 4.7 Editorial Material

HeR2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer

CANCER DISCOVERY (2011)

期刊

CANCER DISCOVERY

卷 1, 期 6, 页码 472-474

出版社

AMER ASSOC CANCER RESEARCH

DOI: 10.1158/2159-8290.CD-11-0261

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

摘要

Primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) drugs are clinically relevant problems in patients with metastatic colorectal carcinoma. A complex network of molecular alterations is involved in this phenomenon. Bertotti et al. report the development of serially transplantable groups of tumor xenografts in immune-deficient mice from patient-derived, genetically characterized metastatic colorectal carcinoma samples. These experimental models (xenopatients) might represent a novel approach to discover and characterize the mechanisms of resistance to anti-EGFR therapy and other molecularly targeted therapies in metastatic colorectal carcinoma. In this respect, Bertotti et al. were able to identify HER2 gene amplification as one such mechanism of resistance to anti-EGFR therapy. Cancer Discovery; 1( 6); 472-74. (C) 2011 AACR.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer

Lu Yang, Arup Bhattacharya, Yun Li, Sandra Sexton, Xiang Ling, Fengzhi Li, Yuesheng Zhang

Summary: Resistance to EGFR inhibitors in colorectal cancer is primarily due to the inability of the inhibitors to downregulate their target. The combination treatment with PEPDG278D overcomes this resistance.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena

Summary: This article reports the final results of a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC). The primary analysis showed an objective response rate (ORR) of 45.3% in HER2-positive patients, while no responses were observed in other HER2 statuses. The most common adverse events of T-DXd were decreased neutrophil count and anemia. These findings support further exploration of T-DXd in HER2-positive mCRC.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy

Meiqin Yuan, Zeng Wang, Wangxia Lv, Hongming Pan

Summary: Currently, the combination of anti-EGFR mAb and chemotherapy is the first-line treatment standard for RAS wild-type mCRC. However, there is ongoing debate regarding the use of anti-EGFR mAb for maintenance treatment after the initial treatment. Despite the lack of evidence from large-scale clinical trials, more studies support the use of anti-EGFR mAb for maintenance therapy, although cost and drug resistance remain concerns.

FRONTIERS IN MOLECULAR BIOSCIENCES (2022)

添加到收藏夹

Article Cell Biology

MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer

Yuanzhou Zhang, Shunshun Liang, Bowen Xiao, Jingying Hu, Yechun Pang, Yuling Liu, Juan Yang, Junpin Ao, Lin Wei, Xiaoying Luo

Summary: This study shows that ErbB3/EGFR receptor tyrosine kinase activity is increased in colorectal cancer cells, and miR-323a-3p can directly target both ErbB3 and EGFR, promoting apoptosis in CRC cells. Furthermore, miR-323a-3p acts as a multi-ErbBs inhibitor, enhancing sensitivity to gefitinib and preventing acquired resistance.

CELL DEATH & DISEASE (2022)

添加到收藏夹

Review Immunology

EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges

Balakarthikeyan Janani, Mayakrishnan Vijayakumar, Kannappan Priya, Jin Hee Kim, D. S. Prabakaran, Mohammad Shahid, Sameer Al-Ghamdi, Mohammed Alsaidan, Nasraddin Othman Bahakim, Mohammad Hassan Abdelzaher, Thiyagarajan Ramesh

Summary: Colorectal carcinoma is a common and lethal form of cancer, with a high rate of metastasis. Targeted nanotherapy, particularly targeting EGFR, has the potential to improve surgical control and reduce tumor-related mortality. Antibodies conjugated with drug-loaded carriers can increase drug effectiveness and quantity delivered to the target site.

VACCINES (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope

Koki Makabe, Takeshi Yokoyama, Shiro Uehara, Tomomi Uchikubo-Kamo, Mikako Shirouzu, Kouki Kimura, Kouhei Tsumoto, Ryutaro Asano, Yoshikazu Tanaka, Izumi Kumagai

Summary: The study focused on the interaction of an antagonistic anti-EGFR antibody clone, 528, with the extracellular region of EGFR. The findings showed that 528 recognizes the tertiary structure of EGFR and competes with EGF and cetuximab for binding, explaining its antagonistic activity.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Editorial Material Urology & Nephrology

A first small step toward personalized immunosuppression

Klemens Budde, Lionel Rostaing

Summary: Lloberas et al. provide further evidence for the benefits of individualized tacrolimus dosing based on population pharmacokinetics and pharmacogenetics. This could prevent underexposure and overexposure and potentially save costs. It could also be the beginning of precision medicine in kidney transplantation, incorporating improved immunologic and donor quality assessments, advanced biopsy readouts, innovative pharmacogenomics for drug safety, and novel diagnostic and outcome algorithms for personalized therapy.

KIDNEY INTERNATIONAL (2023)

添加到收藏夹

Article Oncology

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer

Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani

Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Cell Biology

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

Shanshan Wei, Wenwei Hu, Jun Feng, Yiting Geng

Summary: This paper reviews the research progress of ncRNAs related to anti-EGFR mAbs resistance in CRC, including their expression, signaling network, functional mechanism, relationship with clinical prognosis, and potential therapeutic targets.

CELL COMMUNICATION AND SIGNALING (2022)

添加到收藏夹

Article Nanoscience & Nanotechnology

EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates-Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy

Zixuan Ye, Yue Zhang, Yuanfen Liu, Yanyan Liu, Jiasheng Tu, Yan Shen

Summary: The study successfully synthesized cetuximab-vc-DOX-NPs targeting EGFR-overexpressing tumor cells using bovine serum albumin nanoparticles, showing strong cytotoxicity and tumor inhibition efficacy with low systemic toxicity. In vitro and in vivo studies demonstrated the promising potential of cetuximab-vc-DOX-NPs as a targeted drug delivery system.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)

添加到收藏夹

Article Cell Biology

Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer

Hong Lu, Hao Zhang, Mei-lin Weng, Jin Zhang, Nan Jiang, Juan P. Cata, Duan Ma, Wan-Kun Chen, Chang-Hong Miao

Summary: Morphine treatment can activate MOR and promote proliferation, migration, and invasion in CRC cells, as well as increase resistance to cetuximab. It induces EGFR transactivation, leading to protumoral effects in CRC cell lines.

JOURNAL OF CELLULAR PHYSIOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance

Xinlei Zhuang, Zhe Wang, Jiansheng Fan, Xuefei Bai, Yingchun Xu, James J. Chou, Tingjun Hou, Shuqing Chen, Liqiang Pan

Summary: Researchers have developed a structure-guided and phage-assisted evolution approach to reverse cetuximab resistance mediated by EGFR mutations, without altering the binding epitope or undermining antibody efficacy.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer

Guang Yang, Ling Huang, Hongtao Jia, Batuer Aikemu, Sen Zhang, Yanfei Shao, Hiju Hong, Galiya Yesseyeva, Chenxing Wang, Shuchun Li, Jing Sun, Minhua Zheng, Junjun Ma

Summary: NDRG1 enhances sensitivity to CTX in CRC cells by inhibiting EGFR expression and downstream signaling pathways. NDRG1 also attenuates Cav1-induced endocytosis and degradation of EGFR, thus enhancing CTX activity.

ONCOGENE (2021)

添加到收藏夹

Article Chemistry, Physical

Quantum ESPRESSO: One Further Step toward the Exascale

Ivan Carnimeo, Fabio Affinito, Stefano Baroni, Oscar Baseggio, Laura Bellentani, Riccardo Bertossa, Pietro Davide Delugas, Fabrizio Ferrari Ruffino, Sergio Orlandini, Filippo Spiga, Paolo Giannozzi

Summary: This paper reviews the current status of the Quantum ESPRESSO software suite, which is used for electronic-structure calculations based on plane waves, pseudopotentials, and density-functional theory. The paper focuses on the recent developments in porting the main codes to GPUs using OpenACC and CUDA Fortran offloading. The paper also presents performance benchmarks on different GPU-accelerated architectures for the main codes of the suite.

JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2023)

添加到收藏夹

Editorial Material Plant Sciences

One step further toward a crop CO2-concentrating mechanism

Justin Findinier, Arthur R. Grossman

Summary: The CO2-concentrating mechanism is an inorganic carbon pump used by eukaryotic algae to promote carbon fixation. It has the potential to be transferred to crop species, enhancing agricultural yields and supporting a growing world population.

JOURNAL OF EXPERIMENTAL BOTANY (2023)

添加到收藏夹

Review Oncology

Surgery in Small-Cell Lung Cancer

Nicola Martucci, Alessandro Morabito, Antonello La Rocca, Giuseppe De Luca, Rossella De Cecio, Gerardo Botti, Giuseppe Totaro, Paolo Muto, Carmine Picone, Giovanna Esposito, Nicola Normanno, Carmine La Manna

Summary: Small-cell lung cancer (SCLC) is an aggressive tumor with limited response to chemotherapy and radiotherapy, but surgery may benefit selected early-stage patients. International guidelines recommend surgical intervention in selected stage I SCLC patients after proper evaluation.

CANCERS (2021)

添加到收藏夹

Article Oncology

Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems

Nicola Normanno, Kathi Apostolidis, Francesco de Lorenzo, Philip A. Beer, Raymond Henderson, Richard Sullivan, Andrew V. Biankin, Denis Horgan, Mark Lawler

Summary: Cancer biomarkers are essential for precision oncology, providing personalized treatments and cost-effective healthcare. It is crucial to integrate cancer biomarkers into European health systems and ensure testing is implemented across Europe. However, challenges such as compliance with regulations need to be overcome to fully realize the potential of cancer biomarkers.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives

Davide Ciardiello, Brigida Anna Maiorano, Paola Parente, Maria Grazia Rodriquenz, Tiziana Pia Latiano, Cinzia Chiarazzo, Valerio Pazienza, Luigi Pio Guerrera, Brunella Amoruso, Nicola Normanno, Giulia Martini, Fortunato Ciardiello, Erika Martinelli, Evaristo Maiello

Summary: Biliary tract cancers (BTC) are aggressive tumors with limited therapeutic options. Recent advances in understanding its molecular landscape have provided new possibilities for immunotherapy, but challenges remain. This review critically analyzes completed trials and discusses future directions and potential predictive biomarkers.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Oncology

The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells

Marianna Gallo, Marianeve Carotenuto, Daniela Frezzetti, Rosa Camerlingo, Cristin Roma, Francesca Bergantino, Nicola Normanno, Antonella De Luca

Summary: The study demonstrates that EGFR signaling induces significant changes in miRNA expression, including miR-23c, in MSCs and proposes a novel mechanism of action of miR-23c in basal/claudin-low breast cancer cell lines. These findings contribute to our understanding of the role of EGFR in breast cancer progression and the communication between MSCs and tumor cells.

CANCERS (2022)

添加到收藏夹

Article Oncology

Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis

Francesca Ciccarone, Matteo Bruno, Elisa De Paolis, Alessia Piermattei, Maria De Bonis, Domenica Lorusso, Gian Franco Zannoni, Nicola Normanno, Angelo Minucci, Giovanni Scambia, Gabriella Ferrandina

Summary: Uterine leiomyosarcomas (uLMS) is a rare disease with poor prognosis. Analysis showed that TP53 gene alterations were the most frequent and associated with worse prognosis. Patients with BRCA and HRR-related gene alterations had similar clinical outcomes compared to patients with non-HRR-related gene alterations.

CANCERS (2022)

添加到收藏夹

Article Medicine, General & Internal

Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics

Cristin Roma, Alessandra Sacco, Laura Forgione, Riziero Esposito Abate, Matilde Lambiase, Serena Dotolo, Monica Rosaria Maiello, Daniela Frezzetti, Guglielmo Nasti, Alessandro Morabito, Antonella De Luca, Nicola Normanno

Summary: Targeted sequencing of circulating cell-free DNA is commonly used for the identification of predictive biomarkers in cancer patients. This study found that KRAS mutations associated with clonal hematopoiesis of indeterminate potential are relatively rare in routine clinical diagnostics.

DIAGNOSTICS (2022)

添加到收藏夹

Article Oncology

Access and quality of biomarker testing for precision oncology in Europe

Nicola Normanno, Kathi Apostolidis, Audrey Wolf, Raed Al Dieri, Zandra Deans, Jenni Fairley, Jorg Maas, Antonio Martinez, Holger Moch, Thomas Pilz, Soren Nielsen, Etienne Rouleau, Simon Patton, Victoria Williams

Summary: This article examines the access to and quality of predictive biomarker testing in cancer patients across Europe. The results indicate that countries with public national reimbursement processes have higher access to precision medicines. However, many European countries face limitations in accessing single biomarker tests due to a lack of diagnostic laboratory infrastructure, inefficient organization, and/or insufficient public reimbursement.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Review Oncology

BRAF Inhibitors in Non-Small Cell Lung Cancer

Vincenzo Sforza, Giuliano Palumbo, Priscilla Cascetta, Guido Carillio, Anna Manzo, Agnese Montanino, Claudia Sandomenico, Raffaele Costanzo, Giovanna Esposito, Francesca Laudato, Simona Damiano, Cira Antonietta Forte, Giulia Frosini, Stefano Farese, Maria Carmela Piccirillo, Giacomo Pascarella, Nicola Normanno, Alessandro Morabito

Summary: The identification of BRAF mutations in a small percentage of NSCLC patients has opened up new possibilities for targeted therapy. The combination of dabrafenib and trametinib has shown positive results and good safety profile for BRAF V600E metastatic NSCLC patients. However, there are still many unanswered questions regarding the role of other BRAF inhibitors, resistance mechanisms, and alternative therapeutic strategies for BRAF-mutated NSCLC.

CANCERS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice

Serena Dotolo, Riziero Esposito Abate, Cristin Roma, Davide Guido, Alessia Preziosi, Beatrice Tropea, Fernando Palluzzi, Luciano Giaco, Nicola Normanno

Summary: The use of next-generation sequencing (NGS) techniques is crucial in clinical research and practice, particularly in oncology, for the detection of variants. Reliable and reproducible bioinformatics tools are necessary to extract molecular characteristics from NGS data and determine complex biomarkers. This review explores technologies, algorithms, and models for addressing the identification of complex cancer-associated biomarkers, such as homologous recombination deficiency (HRD), and discusses the future perspectives and challenges faced by bioinformatics in precision medicine.

BIOMEDICINES (2022)

添加到收藏夹

Editorial Material Health Care Sciences & Services

Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center

Camilla Nero, Simona Duranti, Flavia Giacomini, Angelo Minucci, Luciano Giaco, Alessia Piermattei, Maurizio Genuardi, Tina Pasciuto, Andrea Urbani, Gennaro Daniele, Domenica Lorusso, Raffaele Pignataro, Giampaolo Tortora, Nicola Normanno, Giovanni Scambia

Summary: This article presents the workflow adopted by our institution for running a comprehensive cancer genome profiling program in clinical practice, aiming to provide guidance for the application of cancer molecular characterization.

JOURNAL OF PERSONALIZED MEDICINE (2022)

添加到收藏夹

Article Pathology

External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme

Riziero Esposito Abate, Melanie H. Cheetham, Jennifer A. Fairley, Raffaella Pasquale, Alessandra Sacco, Wolstenholme Nicola, Zandra C. Deans, Simon J. Patton, Nicola Normanno

Summary: Tumor mutational burden (TMB) is an agnostic biomarker for immune checkpoint inhibitors, but its testing methods are not standardized. A pilot external quality assessment (EQA) scheme validated the materials and procedures for TMB testing and found significant variability in the results.

VIRCHOWS ARCHIV (2023)

添加到收藏夹

Article Oncology

A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants

Luciano Giaco, Fernando Palluzzi, Davide Guido, Camilla Nero, Flavia Giacomini, Simona Duranti, Emilio Bria, Giampaolo Tortora, Tonia Cenci, Maurizio Martini, Elisa De Paolis, Maria Elisabetta Onori, Maria De Bonis, Nicola Normanno, Giovanni Scambia, Angelo Minucci

Summary: Comprehensive genomic profiling (CGP) is crucial for understanding solid tumors at the molecular level and providing personalized therapy. In this study, the performance of the Illumina TSO500 high-throughput assay was evaluated, showing consistent results with standard approaches and minor limitations, making it suitable for routine patient screening.

CANCERS (2022)

添加到收藏夹

Review Oncology

KRAS in NSCLC: State of the Art and Future Perspectives

Priscilla Cascetta, Arianna Marinello, Chiara Lazzari, Vanesa Gregorc, David Planchard, Roberto Bianco, Nicola Normanno, Alessandro Morabito

Summary: This article reviews the molecular, prognostic, and clinico-pathological characteristics of KRAS mutations in NSCLC patients, as well as current therapeutic strategies and acquired resistance mechanisms. The role of immune-checkpoint inhibitors in KRAS mutant NSCLC patients and ongoing trials are also discussed. The importance of concomitant mutations and the lower-than-expected efficacy of KRAS inhibitors are highlighted.

CANCERS (2022)

添加到收藏夹

Review Oncology

Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing

Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Angela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno

Summary: Cholangiocarcinomas are a heterogeneous group of tumors with distinct genomic alterations. Next-generation sequencing is a powerful tool for identifying gene variants and guiding personalized treatment for patients with cholangiocarcinomas. Understanding the use of NGS in molecular profiling is crucial for healthcare professionals to optimize treatment outcomes.

CANCER TREATMENT REVIEWS (2024)

添加到收藏夹

Article Oncology

Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study

Nicola Normanno, Antonella De Luca, Riziero Esposito Abate, Alessandro Morabito, Michele Milella, Fabrizio Tabbo, Giuseppe Curigliano, Cristina Masini, Paolo Marchetti, Giancarlo Pruneri, Valentina Guarneri, Giovanni L. Frassineti, Gianpiero Fasola, Vincenzo Adamo, Bruno Daniele, Rossana Berardi, Florinda Feroce, Evaristo Maiello, Carmine Pinto

Summary: The Italian Register of Actionable Mutations is a multicentric observational study that collects next-generation sequencing data of patients with advanced solid tumors. The study identifies the rate of actionable mutations and highlights the utility of comprehensive genomic profiling in selected cancer patients.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.